Pittsburgh, PA – Cancer patients who received specialized mental health support as part of their treatment plan are more likely to see improvements in their quality of life and reductions in pain, depression and fatigue, according to a study led by researchers at the University of Pittsburgh School of Medicine....
research News
GRAND RAPIDS, Mich. — A pair of medications that make malignant cells act as if they have a virus could hold new promise for treating colorectal cancers and other solid tumors, reports a study published today in Science Advances. The preclinical research, led by Van Andel Institute scientists, determined how...
Nashville, TN – An international genetic study using multiancestry biobanks has identified novel genetic locations associated with primary open-angle glaucoma (POAG), the most common type of glaucoma and the leading cause of irreversible blindness globally. The findings, published in Cell Reports Medicine, detail ancestry- and sex-specific genetic loci associated with...
PARIS, France – AB Science SA today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating severe systemic mastocytosis (i.e. a medical use patent) with its lead compound masitinib, based on findings from study AB06006. This new European patent...
BOSTON – AbFero Pharmaceuticals, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, today announced the initiation of a Phase 1 study of its lead iron chelator, SP-420, in myelodysplastic (MDS) and myelofibrosis patients (MF) with transfusional iron overload (TIO). “The opening of this trial...
PARIS, FRANCE – Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that four scientific abstracts on its lead drug candidate, obefazimod for the treatment of moderately to...
South San Francisco, Calif. – At Denali Therapeutics, where I serve as chief medical officer and head of development, we are eager to develop new treatments for progressive and debilitating neuronopathic mucopolysaccharidoses diseases with our novel technology. We are not alone—several other biopharma companies also have drug candidates that have...
St. Louis, MO – A drug used to treat children with epilepsy prevents brain tumor formation and growth in two mouse models of neurofibromatosis type 1 (NF1), according to a study by researchers at Washington University School of Medicine in St. Louis. NF1 is a genetic condition that causes tumors...
Uppsala, Sweden – People who have had the herpes virus at some point in their lives are twice as likely to develop dementia compared to those who have never been infected. A new study from Uppsala University confirms previous research on whether herpes can be a possible risk factor for...
London, UK – A single test to speed up diagnosis of a serious disease in pregnant women does not need to be repeated, new research has found. Results from the PARROT-2 trial, published today in the Lancet by researchers from King’s College London and funded by Jon Moulton Charitable Trust,...